113 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast PeerView Press

    • Science
    • 3.0, 4 Ratings

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

    David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

    Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

    • 1 hr 6 min
    Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

    Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

    Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

    • 1 hr 7 min
    Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

    Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

    Go online to PeerView.com/XDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of hematology-oncology experts use the latest guidelines and real-world evidence to explore how the data have influenced clinical decision-making in cancer-associated VTE in different cancer settings. Using clinical scenarios and cases designed to build consensus, the experts illustrate how DOACs can be used to optimally integrate and implement evidence-based strategies for the prevention and treatment of cancer-associated VTE. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.

    • 1 hr 9 min
    "Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?"

    "Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?"

    Go online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how this development can lead to clinical improvements in the prevention and management of VTE in the cancer setting. Upon completion of this activity, participants will be able to: Use established clinical tools to assess the risk for VTE in patients preparing to receive anticancer therapy, Summarize current evidence and guidelines on VTE treatment and prophylaxis including the use of direct oral anticoagulation in patients with cancer, Apply updated evidence on the use of DOACs as initial VTE therapy and/or thromboprophylaxis in the cancer setting.

    • 33 min
    Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

    Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

    Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.

    • 1 hr
    Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

    Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

    Go online to PeerView.com/XBQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

    • 1 hr 9 min

Customer Reviews

3.0 out of 5
4 Ratings

4 Ratings

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press